Brokerages Set Bausch Health Companies Inc. (NYSE:BHC) Target Price at $7.75

Bausch Health Companies Inc. (NYSE:BHC) has earned a consensus rating of “Hold” from the seven ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $7.75.

A number of equities research analysts have commented on the company. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada boosted their target price on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Friday, November 1st. Finally, Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th.

Institutional Investors Weigh In On Bausch Health Companies

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Headlands Technologies LLC bought a new position in Bausch Health Companies during the 2nd quarter worth $35,000. MQS Management LLC acquired a new stake in shares of Bausch Health Companies during the second quarter worth $71,000. Kendall Capital Management purchased a new stake in shares of Bausch Health Companies in the 2nd quarter valued at approximately $87,000. Brown Brothers Harriman & Co. purchased a new stake in Bausch Health Companies in the 2nd quarter worth about $109,000. Finally, Seven Eight Capital LP acquired a new stake in shares of Bausch Health Companies during the second quarter worth approximately $173,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Performance

Shares of Bausch Health Companies stock opened at $7.44 on Thursday. The firm has a fifty day moving average of $7.95 and a two-hundred day moving average of $7.44. The company has a market cap of $2.69 billion, a P/E ratio of -15.49 and a beta of 0.69. Bausch Health Companies has a one year low of $3.96 and a one year high of $11.46.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The business had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter in the prior year, the firm posted $1.03 EPS. The company’s revenue was up 12.2% compared to the same quarter last year. As a group, equities analysts predict that Bausch Health Companies will post 3.73 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.